Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

GH Research Misses Q1 Earnings Estimations but Progresses in Trials

May 15, 2026, 11:16 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The wider-than-expected loss and subsequent price drop indicate negative investor sentiment, reflecting a lack of confidence.

AI summary

What happened, with direct paths to the underlying reporting

GH Research reported a first-quarter loss of 31 cents per share, exceeding losses projected by analysts. Despite the setback, the company affirmed its commitment to the GH001 Phase 3 program, leading analysts to adjust their price targets for the stock, which fell 3.4% post-announcement.

GHRS reported a Q1 loss of 31 cents per share, missing estimates.
Despite losses, CEO notes progress in GH001 Phase 3 program.
Shares fell 3.4% to $21.46 post-earnings announcement.
Citizens maintained Market Outperform rating, lowering price target to $39.
Cantor Fitzgerald raised price target to $35 while maintaining Overweight rating.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

GH Research Misses Q1 Earnings Estimations but Progresses in Trials

GH Research rises on TRD data, FDA hold lift, and Phase 3 progress

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

Depression-Focused GH Research Shares Could See Significant Upside: Analyst